SIM 0708
Alternative Names: SIM-0708Latest Information Update: 16 Nov 2023
At a glance
- Originator Simcere Pharmaceutical Group
- Class Antiasthmatics; Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 01 Nov 2023 SIM 0708 is available for licensing as of 01 Nov 2023. https://en.simcere.com/kfhz/kfhz.aspx
- 01 Nov 2023 Preclinical trials in Alzheimer's disease in China (unspecified route) prior to November 2023 (Simcere Pharmaceutical Group pipeline, November 2023)
- 01 Nov 2023 Preclinical trials in Asthma in China (unspecified route) prior to November 2023 (Simcere Pharmaceutical Group pipeline, November 2023)